anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aqueous suspension of cyclodextrin inclusion complex suppressing coagulation of the cyclodextrin inclusion complex in the water which exhibits poor solubility to water, and keeping an excellent dispersed state for a long time.  &lt;P&gt;SOLUTION: The invention relates to the aqueous suspension of cyclodextrin inclusion complex in which the cyclodextrin inclusion complex expressing poor solubility to water, is suspended in water in the coexistence of cyclodextrins without inclusion of guest molecules. The cyclodextrin inclusion complex with poor solubility to water means that the solubility of the cyclodextrin inclusion complex is 5% or below at 25°C. Preferably, the numbers of glucose units constituting the cyclodextrins without inclusion of a guest molecule and the numbers of glucose units constituting the cyclodextrin inclusion complex are the same. The dispersion can be used in foods such as beverage etc., cosmetics, pharmaceuticals, aqueous paints or the like.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide sheet-type cosmetics enabling efficient permeation of cosmetic material for skin care or the like by preventing evaporation of the cosmetic material caused by using it for hours.  &lt;P&gt;SOLUTION: A sheet-like film 2 having hydrophobicity is adhered and formed onto one face of a nonwoven fabric sheet 1 having water absorptivity by extrusion laminating, and the nonwoven sheet 1 is impregnated with the cosmetic material or the like for obtaining the sheet-type cosmetics as a base structure. Many pinholes 3 are formed in the sheet-like film 2. The nonwoven sheet 1 is formed of a sheet composed of chemical synthetic fiber or chemical synthetic fiber plus natural fiber or natural fiber. The sheet-like film 2 is formed of a polyethylene film or polypropylene film having thickness of 5 μm-40 μm. The resulting sheet is formed by die-cutting so as to obtain a face sheet 5, and hole parts for eyes, an incision part for nose, a hole part for mouth and incision parts for adhering to face are formed so as to provide the sheet-type cosmetics.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
In order to achieve optimum applicational properties of aqueous surfactant solutions, thickeners are added to these solutions. The known thickeners must be added to the surfactant systems in high concentrations which may be, for example in the case of electrolyte thickeners, so high that skin irritations may occur. The novel thickener mixtures do not have these disadvantages. Thickeners for surfactants and surfactant systems are proposed which comprise a mixture of a nonionic surfactant having an HLB value of from 4 to 11 with a polymer. The nonionic surfactant used is a compound of the general formula R-(BO)e(CH2CH2O)f-X and the polymer used is a compound of the general formula x[R&lt;1&gt;-(CH2CH2O)b (BOa]-A-[(BO)c (CH2CH2O)d-R&lt;2&gt;]y. These mixtures do not have the abovementioned disadvantages. A synergistic thickening effect occurs. These thickener mixtures are used in concentrations of only from 0.05 to 10% in surfactants and surfactant systems.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an incense stick for grave-visiting, easily ignitable in a short time.  &lt;P&gt;SOLUTION: The incense stick for grave-visiting 1 comprises a plurality of incenses 2 bundled as an incense bundle 11 wherein the incenses 2a locating on the outermost periphery are set to protrude in a predetermined length from the bundle end face 4 than the bundle end face 4 of the remaining incenses 2b in the bundle axis direction. A recess part 6 recessed inward to the bundle axis direction is formed on the bundle end face 4 of the remaining incenses 2b and housing a candle body 9 on the recess part 6. A combustible material is impregnated or adhered on the adjacent part of the end face part 4 of the incense stick bundle 11. A tool for forming the end face of the incense stick bundle 13 is a bottomed cylindrical body 14 having an upper face aperture to which the incense stick bundle 11 is inserted, and a circumferential grooved part 17 with a predetermined depth and width for housing the incense stick is formed on the peripheral part of the bottom face 16 of the cylindrical body 14.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The cerebrospinal fluid and intracranial pressure are two major reasons why central nervous system is so vulnerable to injuries. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition is comprised of a combination of colloidal osmotic agents and crystal osmotic agents. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition which is dissolved by patient&#39;s own cerebrospinal fluid into subarachnoid spaces. The treatment can be augmented with agents that suppress production of cerebrospinal fluid, or with other known neuroprotective agents.
PURPOSE:To prepare an antibiotic composition preservable for a long period, by using a penicillanic acid salt in combination with an additive composed of cyclic monosaccharide, oligosaccharide, cyclic monosaccharide derivative, and a vitamin having a heterocyclic group containing nitrogen atom. CONSTITUTION:An aqueous solution of the salt of the compound of formulaIis mixed with at least one additive selected from a cyclic monosaccharide (e.g. pentose, hexose, etc.), an oligosaccharide (e.g. disaccharide such as maltulose, trisaccharide such as maltotriose, etc.), a cyclic monosaccharide derivative (e.g. lactone of uronic acid, etc., cyclitol such as bornesitol, etc.) and a vitamin having a heterocyclic group containing nitrogen atom (e.g. vitamin B1, nicotinic acid amide, etc.). The additive is dissolved in the solution, and the solution is freeze- dried to obtain the objective antibiotic composition stable for a long period. Dose: preferably 500-2,000mg/day. The compound of formulaIcan be prepared by reacting the compound of formula II (R is OH-protecting group; Z is halogen) with the compound of formula III (R&#39; is H or protecting group), and removing the protecting group from the product.
Relaxin (RLX), a peptide hormone of the insulin family, has been found to produce impressive effects on the walls of blood vessels, on the blood clotting and on blood lipids and electrolytes, &#34;per se,&#34; and through the stimulation of the synthesis and release of the two powerful substances: Nitric Oxide (NO) and Atrial Natriuretic Peptide (ANP). Experimental studies have shown that administration of RLX increases the blood flow and produces dilation of arteries, influences blood clotting and fibrinolysis and reduces blood lipids. RLX also induces reduction of blood osmolarity and sodium concentration. At the same time, through NO RLX inhibits release of histamine from mastocells. Therefore RLX is proposed as a therapeutic agent to be used in arteriosclerosis and vascular diseases, ischaemia and thrombosis, hypertension and pregnancy&#39;s gestosis. Finally, RLX can also be adopted in other diseases by NO as allergic and inflammatory disorders or by ANP as disfunctions in fluid and electrolytes balance.
The invention relates to a smoking therapy used for treating senile cataract. With the increase of age, cataract occurs to more and more elderly friends. Senile cataract is mainly because of age, environment pollution or prolonged bright light stimulation. If cataract is not treatment in time, cataract may evolve into vision loss in late-stage. Cataract brings a great threat to people&#39;s health. According to current treatment methods, surgery is mainly adopted. The cost is expensive, and the risk is great. The elderly cannot recovery well after surgery. The smoking therapy designed by using traditional Chinese medicine can provide a good therapeutic effect upon patients of senile cataract. The therapy has a lower cost compared to surgery, and has a better effect. The therapy causes no side effect, and patients can recover easily.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent malpractice of dispensation like mix-up of drugs due to a various kind of combinations of drugs in final audit of a prescription drug after dispensing.  &lt;P&gt;SOLUTION: Weight values of various drug 1 by common dosage in bulk packaging 2, weight values of the drugs including a folding material by common dosage 4, and a weight value of folding paper by common number 6, are recorded. A daily dosage weight value by the drug 1 divided by prescription is calculated from the above records. A daily dosage weight value of power is also added in the same way. A daily weight value including folding paper 5 is also calculated. A theoretical weight value is calculated by multiplying them by dosing days. A theoretical weight value of total number of the drugs including the folding material is also calculated from the above records. Subsequently, total weight of a prescription drug which is divided or including the folding material 3 is measured. A weight verification system is to audit weight before or after audit of the prescription drug by verifying the theoretical weight value and the measurement value. A record means puts them to papers like a list or resisters them to a computer by making a database of them for calculating and judging. The theoretical weight value is recorded with prescriptions of each patient, to use it for the subsequent same prescriptions.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
In females during menstrual cycle bleeding occurs which is stopped by releasing organic compounds known as &#39;progesterone&#39; by the body. Excessive uterine hemorrhage is a condition where excessive bleeding occurs and it is presently cured by administering various kinds of allopathic medicines. This invention contemplates the effective and economical treatment of excessive uterine hemorrhage using Coconut Flower extract in a very short period and most importantly without any side effect. The process involves a unique method of preparation of Coconut Flower extract and to produce a medicine there from. The extract contains various organic compounds which at present are being prescribed to the patients in various forms of allopathic medicines along with additional and supplemental medicines to overcome any side effects. Further the treatment period is considerably reduced from 2-6 months as against just 5-7 days using coconut flower extract.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a composition having high antioxidizing activity from bamboo grass and/or bamboo leaves as raw material.  &lt;P&gt;SOLUTION: The method comprises the following procedure: From a lower aliphatic alcohol extract liquid from bamboo grass and/or bamboo leaves, the alcohol is evaporated and substituted by water followed by removing chlorophyll and making a liquid/liquid partition with diethyl ether or the like and separating an aqueous layer liquid. Ethyl acetate is added to the aqueous layer liquid to make a liquid/liquid partition followed by separating an ethyl acetate layer liquid. Then, the objective luteolin 6-C-glucoside is obtained from the aqueous layer or the ethyl acetate layer. By hydrolyzing the lower aliphatic alcohol extract liquid or fractionated liquid, the yield of the objective compound can be improved.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Shaving creams, soaps and sticks, bubble baths and detergent compositions such as toilet soaps comprise, in addition to conventional ingredients, cellulose crystallite aggregates having an average level-off D.P. in the range 15 to 375 anhydroglucose units. A specific example relates to a shaving cream comprising sodium lauryl sulphate, oleic acid and triethanolamine in addition to the cellulose crystallite aggregate.ALSO:Cosmetic compositions of all types comprise cellulose crystallite aggregates, having an average level-off D.P. of from 15 to 375 and which preferably do not contain over 500 p.p.m. of ether-extractable components and which may have a particle size of from less than 1 micron to about 300 microns, and at least one active cosmetic ingredient in an amount sufficient to impart its cosmetic effect.  The compositions, which may be solid, liquid or in &#34;gel&#34; form, may be suitable for use inter alia as a cream, lotion, powder, deodorant, depilatory, sunscreen, lipstick, mascara, rouge, suntan, antiperspirant or dentifrice and may comprise the materials conventionally employed in their formulation in addition to the cellulose material.
FIELD: cosmetology, medicine. SUBSTANCE: invention relates to agents used for face care and treatment of skin diseases. Cosmetic agent comprises a biologically active addition, emulsifying agents, preserving agents, aqueous-spirituous extracts of plants, lavender essential oil, oily component, kaolin and water. Agent has sapropelic curative silt as an active component taken in the amount 0.1-80.0% of total mass of agent. Cosmetic agent has components as emulsifying agents taken among the following group: stearic acid, triethanolamine, emulsion wax taken in any ratios. Cosmetic agent has additionally agidol-1 as an antioxidant. Cosmetic agent has components as preserving agents taken among the following group: nipagin, polydon, hydantoin, caton. Cosmetic agent uses the following plants for preparing aqueous-spirituous extracts: colt&#39;s foot, dandelion, nettle, horse radish, coneflower, Leuzea carthamoides and green tea. Cosmetic agent has soybean oil or burdock oily extract as an oily component. The claimed cosmetic agent shows tonic and nutritive effects on skin, it improves cellular regeneration, gives health shape, elasticity and velvet properties to skin. Agent provides skin whitening, cures acne rash and resorbs scars. EFFECT: enhanced effectiveness, improved properties of agent. 6 cl, 4 ex
The present invention relates to medicine for treating Parkinson&#39;s disease and a processing method thereof. The medicine is prepared from 2 to 15 wt% of velvet bean or extract thereof, 6 to 13 wt% of radix polygoni multiflori preparata, 0.2 to 0.5 wt% of datura flower, 0.5 to 11.5 wt% of ginseng, 2 to 6 wt% of notoginseng, 2 to 9 wt% of angelica, 3 to 11.5 wt% of red sage root, 2 to 11.5 wt% of Fiveleaf Gynostemma Herb, 3 to 11.5 wt% of charred eucommia, 3 to 9 wt% of epimedium herb, 2 to 11.5 wt% of stiff silkorm and 2 to 9 wt% of magnolia bark. During processing, velvet bean seed is mashed and immersed by acetic acid and a diluted alcohol solution for 18 to 24 hours; immersion liquid is decompressed and concentrated by vacuum pumping equipment or corresponding equipment; concentrated liquid is dried at 50 to 60 DEG C to obtain velvet bean extract; after being pulverized, the velvet bean or the extract thereof can be prepared into preparation forms of capsules, pills, etc. according to the conventional method. The present invention corrects the practice that the DA content is increased and the Ach content is reduced in order to achieve abnormal physiological equilibrium during the present traditional PD treatment, and the DA content and the Ach content are simultaneously increased in order to achieve or trend to normal physiological equilibrium needed by human body health. In a word, the present invention solves the equilibrium problem of neurotransmitter, is also capable of exerting the protective function to the antioxidation nerve, thereby reaching the purpose of effectively treating Parkinson&#39;s disease. In addition, the present invention has the advantages of low cost of various components and small toxic and side effect.
Thorpe North &amp; Western, LLP Docket No.: 01235-36028.PCT LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY 5 The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure O-R 10 wherein wherein R is -C13H25 0 or -C 14 H270. One or both of the esters can be present in the pharmaceutical composition. The composition is formulated such that upon single dose administration to a group of human subject, the composition provides a mean serum testosterone Cavg 12-t24 that is within about 35% to about 70% of the mean serum 15 testosterone Cavg to-t24.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a low-irritant and highly safe surface modifier for a denture for preventing, ameliorating or relieving various symptoms caused by dryness in the oral cavity.  &lt;P&gt;SOLUTION: The surface modifier for the denture is characterized as comprising sericin. Wettability of the denture base surface is improved and a reduction in a sense of incompatibility and a pain and a moist feeling in the oral cavity during mounting of the denture are obtained. The sericin has high biocompatibility and is tasteless and odorless. Thereby, the low-irritant and highly safe surface modifier for the denture can be provided. The effects can further be improved by using the sericin and a vegetable extract and/or a polyhydric alcohol in combination.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention provides a traditional Chinese medicine formula for nourishing kidney, promoting blood circulation and dredging collaterals, and belongs to the field of traditional Chinese medicine. The formula of the traditional Chinese medicine consists of the following raw materials: Curculigo orchioides Gaertn., Cnidium monnieri, Morinda officinalis, Herba Epimedii, Cistanche, solomon&#39;s seal, raspberry, the fruit of Chinese magnoliavine, medlar, ophiopogon root, American ginseng, red ginseng, Acanthopanax senticosus, pseudo ginseng, astragalus root, white atractylodes rhizome, Poria cocos, licorice, Rehmannia glutinosa, Chinese angelica, Ligusticum wallichii, Radix Paeoniae Alba, and pure grain liquor. The invention further provides a preparation method of the traditional Chinese medicine formula for nourishing kidney, promoting blood circulation and dredging collaterals. The raw materials of the invention are natural drugs and have no drug resistance, no residue and no side effects. In addition, the formula of the invention is ingenious, and properly matches the rigid and flexible materials to mutually promote and assist, multiply the effect, and reach the effect of enrichment without dryness. Moreover, the traditional Chinese medicine reaches balance of yin and yang of the body, enriches qi and blood, and can actively and effectively improve sexual desire and sexual ability of the elderly. Finally, the traditional Chinese medicine is soaked in liquor into a medicinal liquor, which is convenient for administration, easy to store, and simple for production.
&lt;P&gt;PROBLEM TO BE SOLVED: To inexpensively, selectively and efficiently concentrate/collect resveratrol of a stilbene compound from an extract of Reynoutria japonica Houtt. var. japonica.  &lt;P&gt;SOLUTION: The purification method comprises extracting the root of the Reynoutria japonica Houtt. var. japonica with a mixed liquid of a hydrophilic polar solvent such as ethanol with water, subjecting the extract to absorption by an activated carbon having a peak of pore diameters at about 25-40Å, and subjecting the resultant activated carbon to desorption by a polar solvent such as a lower alcohol and ethyl acetate to selectively obtain the resveratrol in high yield.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Generation of competent embryoids, plantlets and plants (including seeds) from  Cucumis  sp. explant tissue, e.g., from cotyledonary, root, leaf or stem tissue, by induction followed by promotion of embryoid development in a series of media containing one of more of 2,4-D, BAP and NAA under defined temperature, time and light conditions is disclosed. The explant tissue may be from any plant type: wild or cultivated, hybrid (somatic or sexual), or genetically variant or transformed plants. Competent embryoids may be continuously produced by serial subculture. Serial transfer to novel induction and expression media for defined periods causes sequential development of competent embryoids and plantlets. Transfer to development media permits plantlet development, which in turn progress to mature plants in hardening media and/or soil. The process is applicable to producing encapsulated embryoids from single genotypes or somatic hybrids as &#34;artificial seeds&#34;. The process applied to increase of F-1 hybrids permits production of &#34;artificial seeds&#34; (encapsulations) in 1/2 to 1/10 the time it would take to produce natural hybrid seeds. Techniques involving freeze storage and cell suspensions are dislcosed. All representative cultivars were regenerated.
PURPOSE:To obtain a dental sealing material-composition, capable of readily performing filling and removing operation, excellent in sealability and hardly causing abrasion or falling off and having a suitable elasticity after curing. CONSTITUTION:The objective dental sealing material composition comprises (A) 20-90 pts.wt. polymerizable monomer containing &gt;=10wt.% phenoxy-based acrylate monomer of formula I [R is H or methyl; X is 2-4C alkylene; Y is 6-10C alkyl; (n) is 1-10] or formula II, (B) 10-80 pts.wt. filler, inorganic powder, organic powder, organic and inorganic composite material powder without inhibiting the radical reaction or a combination thereof and (C) 0.01-5 pts.wt. polymerization initiator, preferably the photopolymerization initiator composed of a combination of a photosensitizer with a photopolymerization accelerator. Since this composition has moderate elasticity after curing, problems in falling off, deformation or abrasion are hardly caused by effects on absorption of occlusal stress by elasticity when this composition is cured in the cavity of a tooth. Furthermore, the composition can readily be removed as one lump by hollowing out the lump with a tool such as an explorer or an excavator in removing operation.
Assays which centre on the interaction of ATM or related protein kinases with p53 or proteins having similar phosphorylation sites are described. This is based on the discovery that ATM binds DNA and phosphorylates p53 at Ser 15 and Thr 18. The use, particularly the therapeutic use, of p53 fragments or fragments of ATM, or related kinases, to modulate this interaction is also contemplated. The effect of p53 phosphorylation on its interaction with Mdm2 is also discussed. Methods for purifying ATM and ATR involving DNA or Ni-dependent NTA and assays involving the interaction of ATM, or associated kinases, with DNA are also described. Disclosed ATM related kinases include ATR, DNA-protein kinases (DNA-PK). Tor1p, Tor2p, FRAP, FRP1, Tel1p, Mec1p, rad3 and mei-41, preferably ATR and DNA-PK&#39;s.